Table 3 Relation between molecular subtype and clinicopathologic characteristics of MIBC studied cases

Age (mean ± SD) years

62.81 ± 7.6

51.82 ± 5.7

63.45 ± 7.3

P < 0.001*

Sex

P = 0.04*

 Male

23(85.2)

12(54.5)

9 (81.8)

 Female

4(14.8)

10(45.5)

2(18.2)

Tumor Stage

P = 0.016*

 T2

10(37.0)

3(13.6)

2(18.2)

 T3

12(44.4)

6(27.3)

7(63.6)

 T4

5(18.5)

13(59.1)

2(18.2)

Histologic type

P < 0.001*

 Conventional Urothelial

24 (88.9)

0 (0.0)

11 (100)

 UC with squamous differentiation

0 (0.0)

22 (100)

0 (0.0)

 UC with glandular differentiation

3 (11.1)

0 (0.0)

0 (0.0)

Lymph node extension

P = 0.002*

 N0

8 (29.6)

2 (9.1)

3 (27.3)

 N1

15 (55.6)

4 (18.2)

4 (36.4)

 N2

4 (14.8)

16 (72.7)

4 (36.4)

Lymphovascular invasion

P < 0.001*

 Present

5 (18.5)

10(45.5)

6 (54.5)

 Absent

22 (81.5)

12 (54.5)

5 (45.5)

HER2

P < 0.001*

 Negative

18 (66.7)

19(86.4)

11(100)

 Positive

9(33.3)

3(13.6)

0(0.0)

EGFR

P < 0.001*

 Low

21 (77.8)

0 (0)

9(81.8)

 High

6 (22.2)

22 (100.0)

2(18.2)

Response to treatment

0.045*

 Non responders [non-CR^#]

22(81.5)

12(54.5)

10(90.9)

 Responders [CR^#]

5(18.5)

10(45.5)

1(9.1)

Recurrence

0.127

 Positive

6 (22.2)

9 (40.9)

6 (54.5)

 Negative

21 (77.8)

13 (59.1)

5 (45.5)

Death

0.226

 Positive

3(11.1)

4(18.2)

4(36.4)

 Negative

24 (88.9)

18 (81.8)

7 (63.6)